Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We received notice from the UK's MHRA (Medicines and Healthcare Products Regulatory Agency) to pause for now new enrolment into our COPCOV study. We responded promptly to the MHRA, addressing their concerns in detail and await their decision. For now, COPCOV study enrolment is paused around the globe. The safety of our participants is our first priority, as is preventing illness in front-line healthcare workers.

Similar stories

Landmark DeTACT project holds final Investigators’ meeting

On 6-7 May in Zanzibar, Tanzania, the final investigators’ meeting of the Development of Triple Artemisinin-based Combination Therapies (DeTACT) project brought together 35 investigators from participating institutions in Bangladesh, Cambodia, Guinea, Nigeria, Niger, Tanzania, The Gambia, Rwanda, Singapore, and MORU, along with key partners from Fosun Pharma, Medicines for Malaria Venture (MMV), the WHO Global Malaria Programme, and the UK Foreign, Commonwealth and Development Office (FCDO), which funded the project over the past seven years.